Related Experiment Video
Updated: Mar 17, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
CD73-adenosine reduces immune responses and survival in ovarian cancer patients
Pierre-Olivier Gaudreau1, Bertrand Allard1, Martin Turcotte1
1Centre de Recherche du Centre Hospitalier de l'Université de Montréal et Institut du Cancer de Montréal, Québec, Canada; Faculté de Pharmacie, Université de Montréal, Québec, Canada.
Abstract:
Multiple non-redundant immunosuppressive pathways are active within the microenvironment of cancers to avoid tumor eradication by the immune system. Our results demonstrate that the CD73-adenosine pathway is a major immunosuppressive mechanism co-opted by ovarian tumors to escape antitumor immunity. In ovarian cancer patients, high CD73 expression correlates with poor outcome and impaired CD8(+) T cell immunosurveillance.
Insights
The CD73-adenosine pathway helps ovarian tumors evade immune attack. High CD73 expression in patients indicates a poor prognosis and reduced T cell activity against cancer.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Cancer cells utilize immunosuppressive mechanisms to evade immune destruction.
- The tumor microenvironment plays a critical role in regulating immune responses against cancer.
Purpose of the Study:
- To investigate the role of the CD73-adenosine pathway in ovarian cancer immunosuppression.
- To determine the correlation between CD73 expression and patient outcomes in ovarian cancer.
Main Methods:
- Analysis of immunosuppressive pathways in the tumor microenvironment.
- Assessment of CD73 expression in ovarian cancer tissues.
- Correlation analysis between CD73 levels, patient prognosis, and immune cell infiltration.
Main Results:
- The CD73-adenosine pathway is a significant immunosuppressive mechanism in ovarian tumors.
- High CD73 expression is associated with poor clinical outcomes in ovarian cancer patients.
- Elevated CD73 correlates with diminished CD8(+) T cell immunosurveillance.
Conclusions:
- Targeting the CD73-adenosine pathway may represent a therapeutic strategy for ovarian cancer.
- CD73 serves as a potential biomarker for predicting treatment response and patient survival.
